The effect of cyproterone acetate on the growth of children with central precocious puberty.
We have examined the growth and skeletal maturation of 19 children (6 male, 13 female) with central precocious puberty. The aetiology in nine patients (5 male, 4 female) was secondary to a hypothalamic hamartoma. Six children (2 male, 4 female) received no treatment whereas 13 children (4 male, 9 female) were treated with cyproterone acetate in a mean dose of 68 mg/m2 per day (range, 34-260) for a mean duration of 4.5 years (range, 0.8-7.9). There was no significant difference between height SDS for bone age at the beginning and end of observation in either treated or untreated groups. No significant relationship between the mean dose of cyproterone acetate used and change in height SDS for bone age could be determined. We conclude that cyproterone acetate has no beneficial effect on the growth prognosis of children with central precocious puberty.
D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004305:Dose-Response Relationship, Drug; D005260:Female; D006222:Hamartoma / Q000150:complications; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000150:complications; D008297:Male; D011379:Prognosis; D011629:Puberty, Precocious / Q000188:drug therapy*
D017373:Cyproterone Acetate; D003534:Cyproterone